SMT201400117B - Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria - Google Patents

Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria

Info

Publication number
SMT201400117B
SMT201400117B SM201400117T SM201400117T SMT201400117B SM T201400117 B SMT201400117 B SM T201400117B SM 201400117 T SM201400117 T SM 201400117T SM 201400117 T SM201400117 T SM 201400117T SM T201400117 B SMT201400117 B SM T201400117B
Authority
SM
San Marino
Prior art keywords
glyx
treatment method
refractory depression
depression treatment
refractory
Prior art date
Application number
SM201400117T
Other languages
English (en)
Italian (it)
Inventor
Joseph Moskal
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of SMT201400117B publication Critical patent/SMT201400117B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ceramic Products (AREA)
  • Peptides Or Proteins (AREA)
SM201400117T 2009-10-05 2014-08-19 Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria SMT201400117B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24865009P 2009-10-05 2009-10-05
PCT/US2010/051415 WO2011044089A2 (en) 2009-10-05 2010-10-05 Methods of treating depression and other related diseases

Publications (1)

Publication Number Publication Date
SMT201400117B true SMT201400117B (it) 2014-11-10

Family

ID=43857351

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400117T SMT201400117B (it) 2009-10-05 2014-08-19 Glyx-13 per l'uso in un metodo di trattamento della depressione refrattaria

Country Status (12)

Country Link
EP (4) EP3488856A1 (da)
CY (1) CY1118530T1 (da)
DK (2) DK2985032T3 (da)
ES (2) ES2493316T3 (da)
HR (1) HRP20140784T1 (da)
HU (1) HUE043807T2 (da)
PL (2) PL2985032T3 (da)
PT (2) PT2985032T (da)
RS (1) RS53513B1 (da)
SI (1) SI2485751T1 (da)
SM (1) SMT201400117B (da)
WO (1) WO2011044089A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5702288B2 (ja) 2008-09-18 2015-04-15 ノースウエスタン ユニバーシティ Ｎｍｄａレセプターモジュレータ及びその用途
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EA029999B1 (ru) * 2011-04-27 2018-06-29 Нортвестерн Юниверсити Способы лечения аутизма
US20150253305A1 (en) * 2012-10-12 2015-09-10 Northwestern University Methods of identifying compounds for treating depression and other related diseases
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX375286B (es) 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
US20160345855A1 (en) * 2013-12-13 2016-12-01 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
WO2015200322A1 (en) * 2014-06-23 2015-12-30 Northwestern University Methods of treating or ameliorating migraine
SG10201810016XA (en) * 2014-08-14 2018-12-28 Naurex Inc Methods of treating depression using nmda modulators
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
US10591461B2 (en) 2016-04-28 2020-03-17 The Trustees Of The University Of Pennsylvania Method of drug design and optimisation utilizing stereochemical mimicry
JP6823083B2 (ja) 2016-05-19 2021-01-27 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
WO2002072005A2 (en) * 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) * 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders

Also Published As

Publication number Publication date
RS53513B1 (sr) 2015-02-27
DK2485751T3 (da) 2014-08-18
DK2985032T3 (da) 2019-04-15
EP2485751A4 (en) 2013-03-13
EP3488856A1 (en) 2019-05-29
WO2011044089A3 (en) 2012-02-16
PT2485751E (pt) 2014-09-01
EP2813236A1 (en) 2014-12-17
WO2011044089A2 (en) 2011-04-14
CY1118530T1 (el) 2017-07-12
EP2985032B1 (en) 2019-01-02
HUE043807T2 (hu) 2019-09-30
PL2985032T3 (pl) 2019-07-31
EP2485751B1 (en) 2014-05-21
PT2985032T (pt) 2019-04-24
SI2485751T1 (sl) 2014-10-30
EP2485751A2 (en) 2012-08-15
PL2485751T3 (pl) 2014-10-31
ES2721448T3 (es) 2019-07-31
ES2493316T3 (es) 2014-09-11
HRP20140784T1 (hr) 2014-10-10
EP2985032A1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
IL193566A0 (en) Hpv-18-based papillomavirus vaccine
PL3258012T3 (pl) Sztuczny kamień
GB0607088D0 (en) Vaccine
BR112012004593A2 (pt) "método"
IL193661A0 (en) Papillomavirus vaccine
DE602007003596D1 (de) Impfstoff
IL208338A0 (en) Patterned artificial marble slab
GB0616306D0 (en) Vaccines
ZA200902155B (en) IPV-DPT vaccine
PL2013546T3 (pl) Urządzenie podnośnikowe
ZA200901592B (en) Vaccine
GB0614460D0 (en) Vaccines
GB0625593D0 (en) Vaccine
GB0614962D0 (en) Complex for use in vaccines
ZA200808893B (en) HPV-16-Based Papillomavirus vaccine
GB0614476D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0620336D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine
GB0620815D0 (en) Vaccine
GB0619820D0 (en) Vaccine
GB0620337D0 (en) Vaccine
GB0619824D0 (en) Vaccine
GB0614254D0 (en) Vaccine